Clinical Trials Logo

Depressive Disorder, Major clinical trials

View clinical trials related to Depressive Disorder, Major.

Filter by:

NCT ID: NCT03586427 Recruiting - Clinical trials for Depressive Disorder, Major

AGN-241751 in the Treatment of Major Depressive Disorder

Start date: June 13, 2018
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy at 1 day post initial oral dose of AGN-241751 compared with placebo in participants with MDD

NCT ID: NCT03580967 Not yet recruiting - Clinical trials for Major Depressive Disorder

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

Start date: August 1, 2018
Phase: Phase 4
Study type: Interventional

This study will enroll participants who have been diagnosed with type 2 diabetes and are experiencing symptoms of depression. This study will look at an anti-depressant medication called vortioxetine (Trintellix). Vortioxetine is an oral medication (pill) that has been approved by the US Food and Drug Administration (FDA) to treat depression in adults. The purpose of this study is to look at what effects (if any) vortioxetine may have on symptoms of depression in patients with type 2 diabetes. This study will also look at what effects (if any) vortioxetine has on blood sugar, and how vortioxetine may improve the way our brains are able to adapt and respond to stress.

NCT ID: NCT03573349 Not yet recruiting - Clinical trials for Major Depressive Disorder

Glutamate MRS During Ketamine Infusion

Start date: August 2018
Phase: Early Phase 1
Study type: Interventional

This is a feasibility study and the goal of this project is to evaluate whether ACC glutamine, quantified as a CSF-corrected absolute concentration percent change from baseline, is associated with clinical remission, Montgomery Asberg Depression Rating Scale (MADRS) total score of =9, to the anti-glutamatergic antidepressant ketamine. As MRS is expensive, we also aim to study a correlation between peripheral glutamate and central glutamate level.

NCT ID: NCT03571412 Completed - Clinical trials for Major Depressive Disorder

Antidepressive Effect on 5 Herz (Hz) rTMS Over Dorsomedial Prefrontal Cortex and Left Dorsolateral Prefrontal Cortex

Start date: August 8, 2016
Phase: N/A
Study type: Interventional

This study evaluates the efficacy of 5Hz repetitive Transcranial Magnetic Stimulation (rTMS) over Left Dorsolateral Prefrontal Cortex and Dorsomedial Prefrontal Cortex on Major Depressive Disorder (MDD).

NCT ID: NCT03569475 Recruiting - Clinical trials for Major Depressive Disorder

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric (7-17 Years) With Major Depressive Disorder

Start date: July 6, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran compared with placebo in pediatric outpatients (7-17 years) with major depressive disorder (MDD)

NCT ID: NCT03564067 Recruiting - Clinical trials for Major Depressive Disorder

MARt-Depression Trial

Start date: July 5, 2018
Phase: N/A
Study type: Interventional

This is an open label pilot feasibility study that will recruit 15 participants. The purpose of the pilot study will be to evaluate the feasibility of open label Transcranial direct current stimulation (tDCS) in combination with computerized cognitive behavior therapy (cCBT) to maintain wellness following an acute course of Electroconvulsive therapy (ECT) for up to 6 months.

NCT ID: NCT03560518 Recruiting - Clinical trials for Depressive Disorder, Major

Study of Rapastinel as Monotherapy in Patients With MDD

Start date: June 15, 2018
Phase: Phase 3
Study type: Interventional

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).

NCT ID: NCT03559192 Not yet recruiting - Clinical trials for Depressive Disorder, Major

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

Start date: July 9, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder (MDD) partially responsive to selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) treatment in terms of reduction of symptoms of depression, as assessed by the change from baseline on the Montgomery Asberg Depression Rating Scale (MADRS) in non-responders during the placebo lead-in period.

NCT ID: NCT03558256 Recruiting - Clinical trials for Major Depressive Disorder

The Study of Mindfulness-based Cognitive Therapy and Major Depressive Disorder

Start date: May 16, 2016
Phase: N/A
Study type: Interventional

The primary objective of the study is to evaluate the clinical curative effect of mindfulness-based cognitive therapy(MBCT) for major depressive disorder(MDD). Moreover, we will also explore the relationship between P300 potential and erroneous negative potential (ERN) variation and clinical symptoms in MDD and MBCT. This study is a randomized-control trial with two study arms: half of patient cases will receive usual medication treatment with the serotonin reuptake inhibitors (SSRIs) and half of patient cases will receive MBCT added to the usual medication treatment. This study is also a case-control trial, there will be matched normal controls compared with patient cases through a range of psychological scales and electroencephalogram.

NCT ID: NCT03556124 Recruiting - Clinical trials for Major Depressive Disorder

Transcranial Direct Current Stimulation in Major Depression

Start date: February 2, 2018
Phase: N/A
Study type: Interventional

Noninvasive transcranial direct current stimulation (tDCS) is a low-intensity neuromodulation technique of minimal risk that has been used as an experimental procedure for reducing depressive symptoms and symptoms of other brain disorders. Though tDCS applied to prefrontal brain areas is shown to reduce symptoms in some people with major depressive disorder (MDD), the extent of antidepressant response often differs. Methods that map current flow directly in the brain while a person is receiving tDCS and that determine how functional neuroimaging signal changes after a series of tDCS sessions may help us understand how tDCS works, how it can be optimized, and if it can be used as an effective intervention for reducing depressive symptoms. We will investigate these questions in a two-part randomized double blind exploratory clinical trial. The first part of the trial will compare how current flow and functional imaging signal differs in the brain when using tDCS with more focal stimulation, called high definition (HD) tDCS, compared to conventional tDCS (C-tDCS) or sham (non-active) tDCS in patients with MDD. Sixty people with depression (20 in each group) will be randomized to receive either HD-tDCS, C-tDCS or sham-tDCS for a total of 12 sessions each lasting 20 minutes occurring on consecutive weekdays. At the first and last session, subjects will receive 20-30 minutes of active or sham tDCS in the MRI scanner, which will allow us to map tDCS currents, and track changes in regional cerebral blood flow (rCBF) pre-to- post treatment using completely non-invasive methods. At the first and last session and mid-way through the trial, participants will also complete a series of clinical ratings and neurocognitive tests